Literature DB >> 2685955

Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign.

F Fenner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2685955     DOI： 10.1016/s0923-2516(89)80126-8

Source DB:  PubMed          Journal:  Res Virol        ISSN： 0923-2516


× No keyword cloud information.
  20 in total

1.  Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities.

Authors:  Tod J Merkel; Pin-Yu Perera; Vanessa K Kelly; Anita Verma; Zara N Llewellyn; Thomas A Waldmann; Joseph D Mosca; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.

Authors:  Rafal J Zielinski; Jeremy V Smedley; Pin-Yu Perera; Peter M Silvera; Thomas A Waldmann; Jacek Capala; Liyanage P Perera
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

3.  Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Authors:  Aklile Berhanu; Rebecca L Wilson; Dana L Kirkwood-Watts; David S King; Travis K Warren; Susan A Lund; Lindsay L Brown; Alex K Krupkin; Erin Vandermay; Will Weimers; Kady M Honeychurch; Douglas W Grosenbach; Kevin F Jones; Dennis E Hruby
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

4.  Role for CCR5 in dissemination of vaccinia virus in vivo.

Authors:  Ramtin Rahbar; Thomas T Murooka; Eleanor N Fish
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Gregory A Poland
Journal:  Hum Genet       Date:  2012-05-19       Impact factor: 4.132

6.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

7.  Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.

Authors:  J C Ramírez; M M Gherardi; M Esteban
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease.

Authors:  Amanda D Rice; Mathew M Adams; Scott F Lindsey; Daniele M Swetnam; Brandi R Manning; Andrew J Smith; Andrew M Burrage; Greg Wallace; Amy L MacNeill; Richard W Moyer
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

9.  Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans.

Authors:  Bénédicte Puissant-Lubrano; Philippe Bossi; Frederick Gay; Jean-Marc Crance; Olivia Bonduelle; Daniel Garin; François Bricaire; Brigitte Autran; Behazine Combadière
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

10.  Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responses.

Authors:  Nicholas A Siciliano; Adam R Hersperger; Aimee M Lacuanan; Ren-Huan Xu; John Sidney; Alessandro Sette; Luis J Sigal; Laurence C Eisenlohr
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.